Capricor Therapeutics (NASDAQ:CAPR) Shares Down 5.6% – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price traded down 5.6% on Monday . The stock traded as low as $21.93 and last traded at $21.9050. 678,066 shares changed hands during trading, a decline of 47% from the average session volume of 1,270,188 shares. The stock had previously closed at $23.21.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. LADENBURG THALM/SH SH raised shares of Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Piper Sandler restated an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Finally, Roth Capital reaffirmed a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Price Performance

The stock has a market capitalization of $1.33 billion, a P/E ratio of -9.90 and a beta of 0.42. The company’s 50 day simple moving average is $28.39 and its two-hundred day simple moving average is $28.23.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). On average, research analysts anticipate that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $31.70, for a total value of $792,500.00. Following the transaction, the chief financial officer owned 8,223 shares of the company’s stock, valued at approximately $260,669.10. The trade was a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 50,000 shares of company stock valued at $1,551,658 over the last quarter. 9.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Royal Bank of Canada raised its stake in shares of Capricor Therapeutics by 12.4% in the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 557 shares during the last quarter. KBC Group NV bought a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $44,000. ACT Capital Management LLC bought a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $43,000. Nuveen LLC increased its holdings in shares of Capricor Therapeutics by 2.1% in the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock valued at $2,625,000 after purchasing an additional 1,878 shares in the last quarter. Finally, State of Wyoming increased its holdings in shares of Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.